share_log

石藥集團：截至2023年12月31日止年度之全年業績

CSPC PHARMA: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 20 00:06
Summary by Moomoo AI
石藥集團公佈截至2023年12月31日止年度全年業績，總收入達人民幣314.50億元，較2022年增加1.7%。成藥業務收入增長4.6%，原料產品及功能食品等其他業務收入則分別下降9.7%及8.9%。股東應佔溢利為人民幣58.73億元，較去年減少3.6%。每股基本盈利為人民幣52.86分，較去年增加3.2%。董事會建議派發末期股息每股14港仙，全年股息為每股28港仙，較2022年增加33.3%。石藥集團積極拓展國際市場，並持續加大研發投入，研發費用達人民幣48.30億元，佔成藥業務收入的18.8%。公司於年內購回及註銷30,000,000股股份，以提升每股盈利及股東回報。
石藥集團公佈截至2023年12月31日止年度全年業績，總收入達人民幣314.50億元，較2022年增加1.7%。成藥業務收入增長4.6%，原料產品及功能食品等其他業務收入則分別下降9.7%及8.9%。股東應佔溢利為人民幣58.73億元，較去年減少3.6%。每股基本盈利為人民幣52.86分，較去年增加3.2%。董事會建議派發末期股息每股14港仙，全年股息為每股28港仙，較2022年增加33.3%。石藥集團積極拓展國際市場，並持續加大研發投入，研發費用達人民幣48.30億元，佔成藥業務收入的18.8%。公司於年內購回及註銷30,000,000股股份，以提升每股盈利及股東回報。
Petrochemical Group announced its annual results for the year ended 31 December 2023, with total revenues of RMB314.50 billion, an increase of 1.7% compared to 2022. Pharmaceutical revenues grew by 4.6%, while revenues from other businesses such as raw materials and functional foods decreased by 9.7% and 8.9%, respectively. Shareholders accounted for a profit of RMB58.73 billion, down 3.6% year-on-year. Basic earnings per share were RMB52.86, an increase of 3.2% year-on-year. The Board of Directors proposes a final dividend of HK14 cents per share, with a full-year dividend of HK$28 cents per share, an increase of 33.3% compared to 2022. The Petropharmaceutical Group actively expands the international market and continues to increase R&D investments, with R&D expenses of RMB48.30 billion, accounting for 18.8% of the revenue of the pharmaceutical business. The Company repurchased and written off 30,000,000 shares during the year to improve earnings per share and return to shareholders.
Petrochemical Group announced its annual results for the year ended 31 December 2023, with total revenues of RMB314.50 billion, an increase of 1.7% compared to 2022. Pharmaceutical revenues grew by 4.6%, while revenues from other businesses such as raw materials and functional foods decreased by 9.7% and 8.9%, respectively. Shareholders accounted for a profit of RMB58.73 billion, down 3.6% year-on-year. Basic earnings per share were RMB52.86, an increase of 3.2% year-on-year. The Board of Directors proposes a final dividend of HK14 cents per share, with a full-year dividend of HK$28 cents per share, an increase of 33.3% compared to 2022. The Petropharmaceutical Group actively expands the international market and continues to increase R&D investments, with R&D expenses of RMB48.30 billion, accounting for 18.8% of the revenue of the pharmaceutical business. The Company repurchased and written off 30,000,000 shares during the year to improve earnings per share and return to shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more